Evidence map›Paper›PMID 26840567›Full record

ArticleOncotarget2016

Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.

Sarah Cattin, Benoît Fellay, Sylvain Pradervand, Andreas Trojan, Thomas Ruhstaller, Curzio Rüegg, Gregor Fürstenberger

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sarah CattinDepartment of Medicine, Faculty of Science, University of Fribourg, CH-1700 Fribourg, Switzerland.
Benoît FellayCentral Laboratory, HFR Hôpital Cantonal, CH-1700 Fribourg, Switzerland.
Sylvain PradervandGenomic Technologies Facility, Center of Integrative Genomic (CIG), University of Lausanne (UNIL), CH-1015 Lausanne, Switzerland.
Andreas TrojanOnkoZentrum Zürich, CH-8038 Zürich, Switzerland.
Thomas RuhstallerBreast Center, Kantonsspital St.Gallen, CH-9000 St.Gallen, Switzerland.
Curzio RüeggDepartment of Medicine, Faculty of Science, University of Fribourg, CH-1700 Fribourg, Switzerland.
Gregor FürstenbergerTumor and Breast Center ZeTuP, CH-9006 St.Gallen, Switzerland.
Breast Center · CHUniversity of Fribourg · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether bevacizumab exerts its anti-tumor properties through systemic effects beyond local inhibition of angiogenesis and how these effects can be monitored in patients, remain largely elusive. To address these questions, we investigated bone marrow-derived cells and cytokines in the peripheral blood of metastatic breast cancer patients undergoing therapy with bevacizumab.

methodsCirculating endothelial cells (CEC), circulating endothelial progenitor (CEP) and circulating CD11b+ cells in metastatic breast cancer patients before and during therapy with paclitaxel alone (n = 11) or in combination with bevacizumab (n = 10) were characterized using flow cytometry, real time PCR and RNASeq. Circulating factors were measured by ELISA. Aged-matched healthy donors were used as baseline controls (n = 12).

resultsBreast cancer patients had elevated frequencies of CEC, CEP, TIE2+CD11b+ and KIT+CD11b+ cell subsets. CEC decreased during therapy, irrespective of bevacizumab, while TIE2+CD11b+ remained unchanged. KIT+CD11b+ cells decreased in response to paclitaxel with bevacizumab, but not paclitaxel alone. Cancer patients expressed higher mRNA levels of the M2 polarization markers CD163, ARG1 and IL-10 in CD11b+ cells and increased levels of the M2 cytokines IL-10 and CCL20 in plasma. M1 activation markers and cytokines were low or equally expressed in cancer patients compared to healthy donors. Chemotherapy with paclitaxel and bevacizumab, but not with paclitaxel alone, significantly decreased IL-10 mRNA in CD11b+ cells and IL-10 protein in plasma.

conclusionsThis pilot study provides evidence of systemic immunomodulatory effects of bevacizumab and identified circulating KIT+CD11b+ cells and IL-10 as candidate biomarkers of bevacizumab activity in metastatic breast cancer patients.

Indexed as

AdultAgedAngiogenesis InhibitorsBevacizumabBone Marrow CellsBreast NeoplasmsCD11b AntigenEndothelial CellsFemaleHumansInterleukin-10Middle AgedMonocytesPaclitaxelPilot ProjectsProto-Oncogene Proteins c-kitAngiogenesis InhibitorsBevacizumabCD11b AntigenIL10 protein, humanInterleukin-10ITGAM protein, humanPaclitaxelProto-Oncogene Proteins c-kitangiogenesisbreast cancerIL-10KITmonocytes

Identifiers

PMID26840567
PMCPMC4905463
OpenAlexW2290683218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.